WCLC 2025 - Posters & ePosters-P3.12.17 A Phase II Study of Firmonertinib Combined With Apatinib as First-Line Therapy in NSCLC Patients With EGFR Uncommon Mutations

P3.12.17 A Phase II Study of Firmonertinib Combined With Apatinib as First-Line Therapy in NSCLC Patients With EGFR Uncommon Mutations

Asset Subtitle

Huiyang Shi

Meta Tag

Speaker Huiyang Shi

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy